

## SYMLIN (pramlintide) (preferred with clinical PA required) PRIOR AUTHORIZATION FORM

Prior authorization guidelines for **Hypoglycemics, Incretin Mimetics/Enhancers (including Symlin)** and **Quantity Limits/Daily Dose Limits** are available on the DHS Pharmacy Services website at <http://www.dhs.pa.gov/provider/pharmacyservices/index.htm>.

PRIOR AUTHORIZATION REQUEST INFORMATION		PRESCRIBER INFORMATION	
<input type="checkbox"/> New request	<input type="checkbox"/> Renewal request	# of pages: _____	Prescriber name:
Name of office contact:		Specialty:	
Contact's phone number:		State license #:	
LTC facility contact/phone:		NPI:	MA Provider ID#:
BENEFICIARY INFORMATION		Street address:	
Beneficiary name:		Suite #:	City/state/zip:
Beneficiary ID#:	DOB:	Phone:	Fax:

### CLINICAL INFORMATION

<b>Product requested:</b>	<input type="checkbox"/> SymlinPen 60 pen injector	Quantity: _____	Refills: _____
	<input type="checkbox"/> SymlinPen 120 pen injector	Quantity: _____	Refills: _____
Directions:			
Diagnosis ( <i>submit documentation</i> ):		Diagnosis code ( <i>required</i> ):	

#### INITIAL requests

1. What is the beneficiary's diagnosis?	<input type="checkbox"/> Type 1 diabetes	<input type="checkbox"/> Type 2 diabetes
2. What is the beneficiary's most recent hemoglobin A1c?	HbA1c: _____%	Date of test: ____ / ____ / ____
3. Has the beneficiary failed to achieve adequate glycemic control while adherent with optimal insulin therapy?	<input type="checkbox"/> Yes <input type="checkbox"/> No	<i>Submit documentation of insulin regimens tried and outcomes, including HbA1c results.</i>
4. Will the beneficiary be using Symlin in addition to insulin?  List insulins that will be used: _____	<input type="checkbox"/> Yes <input type="checkbox"/> No	<i>Submit documentation of current, complete medication list.</i>
5. <b><i>For a diagnosis of type 2 diabetes</i></b> , does the beneficiary have a history of failure to achieve glycemic control using maximum tolerated doses of metformin or a contraindication or intolerance to metformin?	<input type="checkbox"/> Yes <input type="checkbox"/> No	<i>Submit documentation of HbA1c results and/or contraindications or intolerances.</i>

#### RENEWAL requests

1. Since starting Symlin, did the beneficiary experience improved glycemic control?	<input type="checkbox"/> Yes <input type="checkbox"/> No	<i>Submit documentation of clinical response.</i>
2. What is the beneficiary's most recent hemoglobin A1c (since Symlin was started or last approved)?	HbA1c: _____%	Date of test: ____ / ____ / ____

**PLEASE FAX COMPLETED FORM WITH REQUIRED CLINICAL DOCUMENTATION TO DHS – PHARMACY DIVISION**

<b>Prescriber Signature:</b>	<b>Date:</b>
------------------------------	--------------

**Confidentiality Notice:** The documents accompanying this telecopy may contain confidential information belonging to the sender. The information is intended only for the use of the individual named above. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or taking of any telecopy is strictly prohibited.